Ugochukwu Egolum, MD
Advanced Heart Failure and Transplant Cardiology · Gainesville, GANPI 1558687384
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $184,544 of the $234,592 with a category attached, or 78.7%. It is spread thinly across 36 manufacturers, the largest accounting for just 20.6%. 2025 is the largest year on record at $50,655, 2.4 times the $20,718 reported in 2019. Among advanced heart failure and transplant cardiology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 833 payments — averaging $281.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$48K
- Pfizer$38K
- AstraZeneca$34K
- Actelion Pharmaceuticals US, Inc.$32K
- Akcea Therapeutics, Inc.$25K
- Bridgebio Pharma, Inc.$16K
- plus $40K from 30 others
Across 73 payments — averaging $3615.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$108K
- AstraZeneca$96K
- Boston Scientific$60K
What the payments were for
- Consulting fees$25,49411%
- Speaking & faculty fees$184,54479%
- Travel & lodging$7,7673%
- Food & beverage$16,3787%
- Education$4090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 73 | $48,433 |
| Pfizer | 99 | $38,173 |
| AstraZeneca | 99 | $34,453 |
| Actelion Pharmaceuticals US, Inc. | 110 | $31,765 |
| Akcea Therapeutics, Inc. | 23 | $25,271 |
| Bridgebio Pharma, Inc. | 17 | $16,074 |
| Boehringer Ingelheim | 31 | $14,018 |
| Lilly USA, LLC | 8 | $7,020 |
| Boston Scientific | 13 | $5,448 |
| Merck | 39 | $5,281 |
| Abbott | 74 | $3,562 |
| Novartis | 44 | $765 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 31 | $678 |
| Novo Nordisk | 25 | $440 |
| Amgen | 24 | $398 |
| Cvrx, Inc. | 8 | $396 |
| Daiichi Sankyo Inc. | 22 | $390 |
| Johnson & Johnson | 21 | $344 |
| United Therapeutics Corporation | 12 | $310 |
| Abiomed | 6 | $258 |
| Bayer | 11 | $234 |
| E.r. Squibb & Sons, L.L.C. | 10 | $162 |
| Atricure, Inc. | 1 | $109 |
| Scpharmaceuticals Inc. | 6 | $89 |
| Lexicon Pharmaceuticals, Inc. | 4 | $88 |
| Vifor Pharma, Inc. | 4 | $87 |
| Edwards Lifesciences | 3 | $79 |
| Kestra Medical Technology Services, Inc. | 4 | $69 |
| Philips North America LLC | 3 | $55 |
| Baxter Healthcare | 2 | $32 |
| Ionis Pharmaceuticals, Inc. | 1 | $30 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| GSK | 1 | $18 |
| Impulse Dynamics (USA) Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $16 |
| Janssen Scientific Affairs, LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$36,634
- OPSUMIT$29,868
- UPTRAVI$29,868
- FARXIGA$29,181
- ONPATTRO$21,238
- JARDIANCE$20,674
- AMVUTTRA$17,762
- TEGSEDI$16,432
- Attruby$15,824
- VERQUVO$8,759
- GENERAL - THERAPIES$5,200
- WAINUA$3,759
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,678
- VYNDAMAX$274
- Barostim Neo System$195
- CARDIOMEMS$160
- LifeVest$129
- SYNERGY ABLATION SYSTEM$109
- HeartMate 3 Left Ventricular Dev$107
How this compares
$234,592 in reported general payments places this provider in the 90th percentile of 40 advanced heart failure and transplant cardiology providers in Georgia.
See all advanced heart failure and transplant cardiology providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 84 | $2,540,095 |
| EntrestoSacubitril/Valsartan | 912 | $1,087,375 |
| VyndaqelTafamidis Meglumine | 28 | $660,706 |
| AdempasRiociguat | 45 | $595,939 |
| FarxigaDapagliflozin Propanediol | 460 | $492,778 |
| OpsumitMacitentan | 39 | $469,205 |
| EliquisApixaban | 391 | $408,855 |
| UptraviSelexipag | 16 | $332,168 |
| JardianceEmpagliflozin | 255 | $280,872 |
| WinrevairSotatercept-Csrk | 14 | $177,668 |
| OzempicSemaglutide | 90 | $101,836 |
| XareltoRivaroxaban | 76 | $63,419 |
| Repatha SureclickEvolocumab | 45 | $45,534 |
| VerquvoVericiguat | 19 | $23,340 |
| MounjaroTirzepatide | 22 | $21,626 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $38,173 | $3,609,656503 claims |
| NovartisEntresto | $765 | $1,087,375912 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $31,765 | $801,37355 claims |
| BayerAdempas | $234 | $595,93945 claims |
| AstraZenecaFarxiga | $34,453 | $492,778460 claims |
| Boehringer IngelheimJardiance | $14,018 | $280,872255 claims |
| MerckWinrevair, Verquvo | $5,281 | $201,00833 claims |
| Novo NordiskOzempic | $440 | $101,83690 claims |
| Johnson & JohnsonXarelto | $344 | $63,41976 claims |
| Lilly USA, LLCMounjaro | $7,020 | $21,62622 claims |
| AmgenCorlanor | $398 | $20,15711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 40 advanced heart failure and transplant cardiology providers in Georgia.
Other advanced heart failure and transplant cardiology in Gainesville
- Alanna MorrisGainesville$85K
- Evan HinerGainesville$48K
- Alison BaileyGainesville$28K
- Vikram RajeGainesville$19K
- Giancarlo AcostaGainesville$10K
- Nitya ChandraGainesville$4K
- Lawrence CharlesGainesville$4K
- Andrew DarlingtonFayetteville$1M
- Catherine MartiAthens$343K
- Darshak KariaAugusta$296K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.